|
Balance Sheet Cash Flow Statement 685 Rte. 202/206 Bridgewater, NJ 08807 NJ Tel. 908-541-8600 Fax 908-575-9457 |
Type: Public
On the web:
http://www.enzon.com
Employees:
351
Employee growth: (5.4%)
Enzon Pharmaceuticals has deadly diseases PEGged. The firm's proprietary PEGylation process enhances existing pharmaceutical treatments by attaching a customized molecule to the pharmaceutical; the attachment of the molecule ensures the treatment's longevity in the patient's blood by enabling the pharmaceutical to avoid the immune system's natural response. Enzon's FDA-approved leukemia drug Oncaspar employs PEGylation technology, as does Adagen, an enzyme-replacement therapy for a rare immunodeficiency commonly called "Bubble Boy Disease." Enzon also receives royalties on several PEGylated drugs marketed by others, including Merck's PEG-Intron for hepatitis C and OSI Pharmaceuticals' Macugen.
Key numbers for fiscal year ending December, 2008:
Sales: $196.9M
One year growth: 6.1%
Net income: ($2.7)M
Officers:
Chairman: Alexander J. (Alex) Denner
President, CEO, and Director: Jeffrey H. (Jeff) Buchalter
EVP Finance and CFO: Craig A. Tooman
Competitors:
Genentech
GlaxoSmithKline
Pfizer
